The impact of mavacamten dosing on wall thickness regression: an insight from longer term follow-up based on genetic profile

IF 3.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Said Alsidawi MD , Kaitlin M. Roehl PA , Juan Maria Farina MD , Reza Arsanjani MD , John R. Giudicessi MD, PhD , Jeffrey B. Geske MD , Darrell B. Newman MD , Michael J. Ackerman MD, PhD , Steve R. Ommen MD
{"title":"The impact of mavacamten dosing on wall thickness regression: an insight from longer term follow-up based on genetic profile","authors":"Said Alsidawi MD ,&nbsp;Kaitlin M. Roehl PA ,&nbsp;Juan Maria Farina MD ,&nbsp;Reza Arsanjani MD ,&nbsp;John R. Giudicessi MD, PhD ,&nbsp;Jeffrey B. Geske MD ,&nbsp;Darrell B. Newman MD ,&nbsp;Michael J. Ackerman MD, PhD ,&nbsp;Steve R. Ommen MD","doi":"10.1016/j.ahj.2024.07.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>We have previously reported that genetically positive patients have a more profound early decrease in provocable left ventricular outflow tract gradient compared to genetically negative patients utilizing mavacamten in the first 12 weeks of therapy.</p></div><div><h3>Methods and results</h3><p>In this current analysis, we found that genetically positive patients have less favorable remodeling as measured by left ventricular wall thickness regression when evaluated long-term as compared to genetically negative patients, despite an overall better early response to mavacamten. The majority of genetically positive patients were maintained on only 2.5 mg of mavacamten due to early robust response.</p></div><div><h3>Conclusion</h3><p>We hypothesize that this lower dosing attenuated the long-term benefit of mavacamten in genetically positive patients. We believe that the long-term benefit of mavacamten on positive cardiac remodeling is dose-dependent and not solely related to the magnitude of left ventricular outflow gradient decrease.</p></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"277 ","pages":"Pages 138-141"},"PeriodicalIF":3.7000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002870324001674","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

We have previously reported that genetically positive patients have a more profound early decrease in provocable left ventricular outflow tract gradient compared to genetically negative patients utilizing mavacamten in the first 12 weeks of therapy.

Methods and results

In this current analysis, we found that genetically positive patients have less favorable remodeling as measured by left ventricular wall thickness regression when evaluated long-term as compared to genetically negative patients, despite an overall better early response to mavacamten. The majority of genetically positive patients were maintained on only 2.5 mg of mavacamten due to early robust response.

Conclusion

We hypothesize that this lower dosing attenuated the long-term benefit of mavacamten in genetically positive patients. We believe that the long-term benefit of mavacamten on positive cardiac remodeling is dose-dependent and not solely related to the magnitude of left ventricular outflow gradient decrease.

马伐康坦剂量对壁厚回归的影响:基于基因图谱的长期跟踪观察
方法和结果在目前的分析中,我们发现基因阳性患者与基因阴性患者相比,尽管对马伐康汀的早期反应总体较好,但在长期评估时,以左室壁厚度回归衡量,基因阳性患者的重塑效果不如基因阴性患者。由于早期反应较强,大多数基因阳性患者只服用了 2.5 毫克的马伐康坦。结论我们假设,这种较低的剂量削弱了马伐康坦对基因阳性患者的长期益处。我们认为,马伐康坦对心脏正重塑的长期益处与剂量有关,而不仅仅与左室流出阶差的降低幅度有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American heart journal
American heart journal 医学-心血管系统
CiteScore
8.20
自引率
2.10%
发文量
214
审稿时长
38 days
期刊介绍: The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信